Clearmind Medicine's Patent Advance: A Breakthrough in Addiction Treatment

Author: Addison Perry Updated: 03-10-2025 07:32 AM

Innovative Patent Publication by Clearmind Medicine

Clearmind Medicine Inc. (NASDAQ: CMND) has made an exciting announcement regarding its latest patent publication aimed at addressing cocaine addiction.

Research Backed by Leading Experts

The patent, recently published by the Korean Intellectual Property Office, reveals Clearmind's cutting-edge combination therapy utilizing MEAI and N-Acylethanolamines. This innovative approach leverages findings from preclinical trials conducted by Professor Gal Yadid and his team at Bar-Ilan University in Israel.

Significant Findings from Preclinical Trials

In these pivotal trials, animals treated with MEAI showcased a notable decrease in cravings associated with cocaine use. Further studies indicated that MEAI effectively reduces cocaine-seeking behavior without compromising the animals' responsiveness to natural rewards. This crucial result underscores MEAI's targeted action on addiction mechanisms rather than general reward pathways.

Collaborative Efforts with SciSparc Ltd.

Clearmind's patent publication is a part of its strategic collaboration with SciSparc Ltd. (NASDAQ: SPRC), focusing on integrating Clearmind's groundbreaking MEAI therapy with SciSparc's PEA. This partnership highlights the commitment of both companies to develop effective treatments for central nervous system disorders.

About Clearmind Medicine Inc.

Clearmind is dedicated to discovering and developing new psychedelic-based therapeutics that address significant health challenges, including addiction. Their mission extends to commercializing these compounds as regulated medicines, foods, or supplements.

Intellectual Property Portfolio

The company boasts an impressive array of nineteen patent families, which includes 31 granted patents. Clearmind remains proactive in seeking additional patents to fortify its intellectual property, ensuring a robust platform for their unique therapeutic innovations.

Stock and Financial Information

Shares of Clearmind Medicine are actively traded on the Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange as "CWY0." Investors keen on the psychedelic therapy sector may take a close look at this stock as Clearmind progresses on its innovative path.

Company Contact Information

For inquiries, you can reach out to Clearmind's investor relations through email at invest@clearmindmedicine.com or by telephone at (604) 260-1566. Additional information can be found on their official website: www.clearmindmedicine.com.

Frequently Asked Questions

What is Clearmind Medicine known for?

Clearmind Medicine is focused on developing psychedelic-derived treatments that address major health issues like addiction.

What therapy has Clearmind patented?

They have patented a combination therapy utilizing MEAI and N-Acylethanolamines for cocaine addiction treatment.

Who conducted the preclinical trials for Clearmind's research?

The trials were conducted by Professor Gal Yadid and his research team at Bar-Ilan University in Israel.

How does MEAI therapy work?

MEAI therapy is designed to reduce cravings for cocaine without affecting the desire for natural rewards.

Where can I find more information about Clearmind Medicine?

You can visit their website at www.clearmindmedicine.com for more details.

About The Author

Hello, I'm 30-year-old financial writer and expert Addison Perry, and I love to simplify the intricacies of the financial industry. I've committed myself over the years to deciphering the subtleties of investing techniques and economic trends and converting them into doable guidance that anybody can use. My goal with writings and books is to make money interesting and approachable so that readers may take charge of their financial futures.

My enthusiasm to empowerment and education has propelled me through my career in finance. I write because I think that everyone should be able to make educated financial decisions, and I try to provide that. Regardless of experience level with investing, my work is intended to provide insightful analysis and practical advice to enable you to thrive in the always changing financial environment. I appreciate you traveling with me toward success and financial literacy.

Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.